GlassScriptPhysician profile
Puja Chitkara
NPI 1871718189
$144,914.72
in general payments reported to CMS, 2019-2025
37 companies · $34K in 2025
The $34K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,920 · 2020: $24K · 2021: $27K · 2022: $8,968 · 2023: $20K · 2024: $22K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Consulting Fee: $18K · Food and Beverage: $15K · Travel and Lodging: $3,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,671.00 |
| Consulting Fee | $18,341.50 |
| Food and Beverage | $15,133.23 |
| Travel and Lodging | $3,007.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $42,971.82 | 2019-2025 | Otezla, Enbrel, Tavneos |
| Genzyme Corporation | $37,835.29 | 2019-2025 | |
| Ucb, INC. | $22,617.24 | 2019-2025 | Bimzelx, Cimzia |
| Aurinia Pharma U.S., INC. | $15,844.25 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $11,706.47 | 2019-2025 | Benlysta, Nucala |
| Novartis Pharmaceuticals Corporation | $3,091.30 | 2019-2025 | |
| Abbvie INC. | $2,911.72 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Regeneron Healthcare Solutions, INC. | $1,113.00 | 2019 | |
| Horizon Therapeutics Plc | $966.69 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $918.30 | 2021-2025 | Saphnelo |
| Janssen Biotech, INC. | $909.66 | 2019-2025 | Tremfya, Simponi Aria |
| Lilly USA, LLC | $632.95 | 2019-2025 | Taltz, Olumiant, Zepbound |
| Pfizer INC. | $480.37 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $443.66 | 2019-2025 | Orencia, Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.06 | 2019-2025 | Ofev, Spevigo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $325.80 | 2020-2025 | Acthar |
| Janssen Scientific Affairs, LLC | $245.49 | 2019-2022 | |
| Genentech USA, INC. | $227.64 | 2019-2025 | Actemra, Gazyva |
| Ani Pharmaceuticals, INC. | $227.61 | 2024 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $126.08 | 2019-2025 | Opsumit, Uptravi |
| Teva Pharmaceuticals USA, INC. | $120.68 | 2023 | Austedo Xr |
| Neurelis, INC. | $117.93 | 2025 | Valtoco |
| Janssen Pharmaceuticals, INC | $101.03 | 2021 | |
| Depuy Synthes Sales INC. | $97.08 | 2019-2023 | Orthovisc |
| Sanofi-Aventis U.S. LLC | $83.75 | 2019-2020 | |
| Medexus Pharma, INC. | $62.71 | 2019 | |
| Radius Health, INC. | $53.63 | 2019-2020 | |
| Coloplast Corp | $52.55 | 2019 | |
| Celgene Corporation | $45.53 | 2019 | |
| Scilex Pharmaceuticals INC. | $41.85 | 2024 | |
| Bioventus LLC | $36.29 | 2024 | Supartz Fx Sodium Hyaluronate, Durolane |
| Mallinckrodt Enterprises LLC | $33.51 | 2019 | |
| Alexion Pharmaceuticals, INC. | $29.56 | 2024 | Strensiq |
| Sobi, INC | $26.98 | 2023 | |
| Organon LLC | $24.74 | 2023 | Hadlima |
| Gilead Sciences, INC. | $23.89 | 2020 | |
| Pacira Therapeutics, INC. | $18.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puja Chitkara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.